The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed because of a cast error
Error code: DatasetGenerationCastError
Exception: DatasetGenerationCastError
Message: An error occurred while generating the dataset
All the data files must have the same columns, but at some point there are 10 new columns ({'mutant_rank', 'mut_Rank_Stab', 'mut_netchop_score_ct', 'mutant_rank_PRIME', 'mutant_other_significant_alleles', 'mutant_seq', 'seq_len', 'TAP_score', 'mutant_rank_netMHCpan', 'wt_seq'}) and 31 missing columns ({'HLA', 'anchor_mutation', 'pubmed_id', 'genomic_coord', 'mt_peptide', 'netmhcpan_rank', 'tumor_type_detail', 'netmhcstabpan_stability', 'length', 'effector_origin', 'wt_peptide', 'assay_type', 'dai_netmhcpan', 'bigmhc_im_score', 'mutation_type', 'presentation_method', 'ndd_id', 'reference_name', 'ref', 'eluted_ligand_match', 'position', 'tcga_cancer_expression_tpm_median', 'mutation', 'alt', 'prime_rank', 'driver_status', 'chromosome', 'tap_score', 'stimulation_target', 'tumor_tissue', 'netchop_score'}).
This happened while the csv dataset builder was generating data using
hf://datasets/NeoDiscovery/NDD/data/leaderboard/nip_leaderboard_train.tsv (at revision f4d033289b4846e6a9bc50efd5ed847e438bdd2e)
Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)
Traceback: Traceback (most recent call last):
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1831, in _prepare_split_single
writer.write_table(table)
File "/usr/local/lib/python3.12/site-packages/datasets/arrow_writer.py", line 714, in write_table
pa_table = table_cast(pa_table, self._schema)
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.12/site-packages/datasets/table.py", line 2272, in table_cast
return cast_table_to_schema(table, schema)
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.12/site-packages/datasets/table.py", line 2218, in cast_table_to_schema
raise CastError(
datasets.table.CastError: Couldn't cast
patient_id: string
response_type: string
gene: string
mutant_seq: string
wt_seq: string
seq_len: int64
mutant_rank_netMHCpan: double
mutant_rank: double
mutant_other_significant_alleles: int64
mutant_rank_PRIME: double
TAP_score: double
mut_Rank_Stab: double
mut_netchop_score_ct: double
-- schema metadata --
pandas: '{"index_columns": [{"kind": "range", "name": null, "start": 0, "' + 1909
to
{'ndd_id': Value('string'), 'patient_id': Value('string'), 'tumor_tissue': Value('string'), 'tumor_type_detail': Value('string'), 'gene': Value('string'), 'mutation_type': Value('string'), 'mutation': Value('string'), 'position': Value('string'), 'mt_peptide': Value('string'), 'wt_peptide': Value('string'), 'length': Value('int64'), 'chromosome': Value('string'), 'genomic_coord': Value('string'), 'ref': Value('string'), 'alt': Value('string'), 'HLA': Value('string'), 'response_type': Value('string'), 'assay_type': Value('string'), 'effector_origin': Value('string'), 'stimulation_target': Value('string'), 'presentation_method': Value('string'), 'netmhcpan_rank': Value('float64'), 'netmhcstabpan_stability': Value('float64'), 'prime_rank': Value('float64'), 'bigmhc_im_score': Value('float64'), 'tap_score': Value('float64'), 'netchop_score': Value('float64'), 'dai_netmhcpan': Value('float64'), 'anchor_mutation': Value('string'), 'eluted_ligand_match': Value('int64'), 'tcga_cancer_expression_tpm_median': Value('float64'), 'driver_status': Value('string'), 'pubmed_id': Value('string'), 'reference_name': Value('string')}
because column names don't match
During handling of the above exception, another exception occurred:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1455, in compute_config_parquet_and_info_response
parquet_operations = convert_to_parquet(builder)
^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1054, in convert_to_parquet
builder.download_and_prepare(
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 894, in download_and_prepare
self._download_and_prepare(
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 970, in _download_and_prepare
self._prepare_split(split_generator, **prepare_split_kwargs)
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1702, in _prepare_split
for job_id, done, content in self._prepare_split_single(
^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.12/site-packages/datasets/builder.py", line 1833, in _prepare_split_single
raise DatasetGenerationCastError.from_cast_error(
datasets.exceptions.DatasetGenerationCastError: An error occurred while generating the dataset
All the data files must have the same columns, but at some point there are 10 new columns ({'mutant_rank', 'mut_Rank_Stab', 'mut_netchop_score_ct', 'mutant_rank_PRIME', 'mutant_other_significant_alleles', 'mutant_seq', 'seq_len', 'TAP_score', 'mutant_rank_netMHCpan', 'wt_seq'}) and 31 missing columns ({'HLA', 'anchor_mutation', 'pubmed_id', 'genomic_coord', 'mt_peptide', 'netmhcpan_rank', 'tumor_type_detail', 'netmhcstabpan_stability', 'length', 'effector_origin', 'wt_peptide', 'assay_type', 'dai_netmhcpan', 'bigmhc_im_score', 'mutation_type', 'presentation_method', 'ndd_id', 'reference_name', 'ref', 'eluted_ligand_match', 'position', 'tcga_cancer_expression_tpm_median', 'mutation', 'alt', 'prime_rank', 'driver_status', 'chromosome', 'tap_score', 'stimulation_target', 'tumor_tissue', 'netchop_score'}).
This happened while the csv dataset builder was generating data using
hf://datasets/NeoDiscovery/NDD/data/leaderboard/nip_leaderboard_train.tsv (at revision f4d033289b4846e6a9bc50efd5ed847e438bdd2e)
Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
ndd_id string | patient_id string | tumor_tissue string | tumor_type_detail string | gene string | mutation_type string | mutation string | position string | mt_peptide string | wt_peptide string | length int64 | chromosome string | genomic_coord string | ref string | alt string | HLA string | response_type string | assay_type string | effector_origin string | stimulation_target string | presentation_method string | netmhcpan_rank float64 | netmhcstabpan_stability float64 | prime_rank float64 | bigmhc_im_score float64 | tap_score float64 | netchop_score float64 | dai_netmhcpan float64 | anchor_mutation string | eluted_ligand_match int64 | tcga_cancer_expression_tpm_median float64 | driver_status string | pubmed_id string | reference_name string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NDDR-8Y7QQTRFWC-U | GEXOATK7 | Skin | Skin Cutaneous Melanoma | WDR46 | SNV | p.T227I | 3 | FLIYLDVSV | FLTYLDVSV | 9 | 6 | 33287207 | G | A | HLA-A02:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC, tumor_cells | none | 0.123 | 0.17 | 0.124 | 0.500021 | 0.2 | 0.152263 | -0.198451 | no | 1 | 5.306263 | null | PMID:33303615 | Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer |
NDDR-2HJHFX0EFJ-0 | GEXOATK7 | Skin | Skin Cutaneous Melanoma | AHNAK | SNV | p.S4460F | 1 | FMPDFDLHL | SMPDFDLHL | 9 | 11 | 62526678 | G | A | HLA-A02:01 | CD8 | ELISPOT, ICS, multimer | patient_TIL | peptide_pulsed_APC | none | 0.057 | 0.3 | 0.053 | 0.582847 | 0.782 | 0.978539 | -0.816761 | no | 1 | 4.897806 | Other Tumor Driver | PMID:33303615 | Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer |
NDDR-M2GXDWKP1W-D | ZWHDI5GT | Skin | Skin Cutaneous Melanoma | GNB5 | SNV | p.P377L | 9 | RVSTLRVSL | RVSTLRVSP | 9 | 15 | 52124519 | G | A | HLA-B07:02 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.139 | 0.8 | 0.088 | 0.476441 | 1.286 | 0.034531 | -3.435379 | no | 0 | 0.389732 | null | PMID:33303615 | Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer |
NDDR-JRGCAYDCQA-S | 6FHDB5EK | Skin | Skin Cutaneous Melanoma | TRAPPC1 | SNV | p.R129G | 4 | FRSGLDSYV | FRSRLDSYV | 9 | 17 | 7930659 | G | C | HLA-C06:02 | CD8 | 51Cr, HLA-block | patient_Tc_line | peptide_pulsed_APC, tumor_cells | endogenous(HLA-block) | 0.1 | 29 | 0.018 | 0.380201 | 0.366 | 0.73499 | -0.41871 | no | 1 | 5.942411 | null | PMID:10582700 | Two antigens recognized by autologous cytolytic T lymphocytes on a Melanoma result from a single point mutation |
NDDR-VXMQ2DHCNY-F | DAXCBTFA | Skin | Skin Cutaneous Melanoma | TRAPPC1 | SNV | p.R129G | 7 | SELFRSGLDSY | SELFRSRLDSY | 11 | 17 | 7930659 | G | C | HLA-B44:02 | CD8 | 51Cr, HLA-block | patient_Tc_line | peptide_pulsed_APC, tumor_cells | endogenous(HLA-block) | 0.266 | 0.4 | 0.581 | 0.052169 | 3.04 | 0.763436 | 0.158546 | no | 1 | 5.942411 | null | PMID:10582700 | Two antigens recognized by autologous cytolytic T lymphocytes on a Melanoma result from a single point mutation |
NDDR-AHCH9CD88T-A | M4HZA63S | Skin | Skin Cutaneous Melanoma | HERV-K-MEL | SNV | p.V102I | 5 | MLAVISCAV | MLAVVSCAV | 9 | null | null | null | null | HLA-A02:01 | CD8 | 51Cr, HLA-block | patient_Tc_line | peptide_pulsed_APC, tumor_cells | endogenous(HLA-block) | 1.022 | 0.3 | 0.553 | 0.416587 | 0.378 | null | -0.068993 | no | 0 | null | null | PMID:12359761 | A human endogenous retroviral sequence encoding an antigen recognized on Melanoma by cytolytic T lymphocytes |
NDDR-MG2GYB7FKK-1 | LFXUCEDT | Skin | Skin Cutaneous Melanoma | PRDX5 | SNV | p.S79L | 6 | LLLDDLLVSI | LLLDDSLVSI | 10 | 11 | 64321032 | C | T | HLA-A02:01 | CD8 | 51Cr, HLA-block, multimer | patient_Tc_line, patient_TIL | peptide_pulsed_APC, tumor_cells | endogenous(HLA-block) | 0.171 | 0.4 | 0.046 | 0.535931 | 0.624 | 0.954141 | 0.047913 | no | 1 | 7.68365 | null | PMID:15695408 | Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic Melanoma and targeted by CD8(+) T cells with a memory phenotype |
NDDR-3Q45K91QR4-F | D35NTCNS | Skin | Skin Cutaneous Melanoma | MYO1B | SNV | p.E911K | 1 | KINKNPKYK | EINKNPKYK | 9 | 2 | 191414079 | G | A | HLA-A03:01 | CD8 | 51Cr, HLA-block, multimer | patient_Tc_line, patient_TIL | peptide_pulsed_APC, tumor_cells | endogenous(HLA-block) | 0.024 | 0.2 | 0.013 | 0.446357 | 0.552 | 0.634706 | -4.044512 | no | 1 | 3.642422 | null | PMID:10064075 | A natural cytotoxic T cell response in a spontaneously regressing human Melanoma targets a neoantigen resulting from a somatic point mutation |
NDDR-7SABVDNYFG-Y | TSXDFNM6 | Head & Neck | Head and Neck Squamous Cell Carcinoma | TP53 | SNV | p.Y220C | 4 | VVPCEPPEV | VVPYEPPEV | 9 | null | null | null | null | HLA-A02:01 | CD8 | 51Cr, HLA-block | patient_Tc_line | peptide_pulsed_APC, tumor_cells | endogenous(HLA-block) | 0.751 | 9 | 1.073 | 0.317315 | 0.454 | 0.687508 | 0.629941 | no | 1 | 3.293914 | Tumor Driver | PMID:17294448 | Immunological characterization of missense mutations occurring within cytotoxic T cell defined p53 epitopes in HLA A0201 squamous cell carcinomas of the head and neck |
NDDR-GSSA542C57-I | 7LJZLSYK | Skin | Skin Cutaneous Melanoma | ENTPD4 | SNV | p.P85L | 7 | ATDTNNLNVNY | ATDTNNPNVNY | 11 | 8 | 23447838 | G | A | HLA-A11:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | none | 2.391 | 4.5 | 1.282 | 0.364496 | 2.864 | 0.96242 | 0.671223 | no | 0 | 3.119629 | null | PMID:33038342 | Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction |
NDDR-SGEY1B756Q-7 | 7LJZLSYK | Skin | Skin Cutaneous Melanoma | TTC37 | SNV | p.A692V | 6 | YLDGKVVDY | YLDGKAVDY | 9 | 5 | 95520755 | G | A | HLA-A11:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | none | 3.937 | 35 | 11.33 | 0.307559 | 2.426 | null | -0.116625 | no | 0 | 3.005436 | null | PMID:33038342 | Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction |
NDDR-WSV1MDSJB6-H | TFT6DO6A | Skin | Skin Cutaneous Melanoma | ARMT1 | SNV | p.P286L | 2 | FYGKTILWF | FPGKTILWF | 9 | 6 | 151468641 | C | T | HLA-A24:02 | CD8 | ELISPOT, ICS, multimer | PBMC_postVax | peptide_pulsed_APC | none | 0.052 | 0.25 | 0.02 | 0.351818 | 2.108 | null | -4.193145 | no | 0 | 2.896756 | null | PMID:30880120 | Identification of a neoantigen epitope in a Melanoma patient with good response to anti-PD-1 antibody therapy |
NDDR-XMMWH86R9X-E | FNWFEVPE | Cerebellum/Posterior fossa | Medulloblastoma (pediatric) | PDCD10 | SNV | p.A74P | 4 | IASPIKEL | IASAIKEL | 8 | 3 | 167687680 | C | G | HLA-C12:02 | CD8 | ELISPOT, ICS, multimer | patient_Tc_line, PBMC_pre | peptide_pulsed_APC | none | 0.234 | 2.5 | 3.957 | 0.149582 | 0.99 | 0.48951 | -1.082819 | no | 0 | null | null | PMID:31351799 | Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy |
NDDR-BBEYF3X3HN-4 | FNWFEVPE | Cerebellum/Posterior fossa | Medulloblastoma (pediatric) | PDCD10 | SNV | p.A74P | 10 | LQTIKDIASPI | LQTIKDIASAI | 11 | 3 | 167687680 | C | G | HLA-B52:01 | CD8 | ELISPOT, ICS, multimer | patient_Tc_line, PBMC_pre | peptide_pulsed_APC | none | 7.046 | 0.4 | 10.695 | 0.000387 | 0.728 | 0.897295 | 0.649004 | no | 0 | null | null | PMID:31351799 | Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy |
NDDR-8FNTWKZDFG-Y | FU5SPZUA | Cerebellum/Posterior fossa | Medulloblastoma (pediatric) | TSEN54 | SNV | p.R472Q | 2 | AQMCISGF | ARMCISGF | 8 | 17 | 75523764 | G | A | HLA-C12:03 | CD8 | ELISPOT, ICS, multimer | patient_Tc_line, PBMC_pre | peptide_pulsed_APC | none | 22.864 | 1.2 | 33.066 | 0.003008 | 3.142 | 0.307014 | -0.193672 | yes | 0 | null | null | PMID:31351799 | Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy |
NDDR-JDQYDNJXFT-A | FU5SPZUA | Cerebellum/Posterior fossa | Medulloblastoma (pediatric) | PCSK9 | SNV | p.V202F | 11 | DHREIEGRVMF | DHREIEGRVMV | 11 | 1 | 55052358 | G | T | HLA-B18:01 | CD8 | ELISPOT, ICS, multimer | patient_Tc_line, PBMC_pre | peptide_pulsed_APC | none | 0.158 | 12 | 1.548 | 0.145635 | 2.264 | 0.536006 | -2.522178 | no | 0 | null | null | PMID:31351799 | Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy |
NDDR-0J9XF0AJTT-A | FU5SPZUA | Cerebellum/Posterior fossa | Medulloblastoma (pediatric) | PCSK9 | SNV | p.V202F | 1 | FTDFENVP | VTDFENVP | 8 | 1 | 55052358 | G | T | HLA-C05:01 | CD8 | ELISPOT, ICS, multimer | patient_Tc_line, PBMC_pre | peptide_pulsed_APC | none | 9.493 | 45 | 8.173 | 0.146671 | -0.474 | 0.405231 | -0.296779 | no | 0 | null | null | PMID:31351799 | Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy |
NDDR-0V67NT0BT2-D | FU5SPZUA | Cerebellum/Posterior fossa | Medulloblastoma (pediatric) | NEU2 | SNV | p.L234T | 9 | KTGEQRVVTL | KTGEQRVVLL | 10 | 2 | 233034587 | G | A | HLA-C12:03 | CD8 | ELISPOT, ICS, multimer | patient_Tc_line, PBMC_pre | peptide_pulsed_APC | none | 9.571 | 5.5 | 5.727 | 0.004257 | 0.814 | null | -0.381034 | yes | 0 | null | null | PMID:31351799 | Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy |
NDDR-9A9KVDPVGD-V | FU5SPZUA | Cerebellum/Posterior fossa | Medulloblastoma (pediatric) | SVIL | SNV | p.D1285N | 8 | RTDVKAYNVT | RTDVKAYDVT | 10 | null | null | null | null | HLA-C05:01 | CD8 | ELISPOT, ICS, multimer | patient_Tc_line, PBMC_pre | peptide_pulsed_APC | none | 12.052 | 31 | 3.575 | 0.175771 | -0.81 | 0.027018 | -0.39557 | no | 0 | null | null | PMID:31351799 | Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy |
NDDR-NB93YAHBJ0-B | 4V2JUJEQ | Liver | Hepatocellular Carcinoma | C5orf42 | SNV | p.I1134K | 13 | DADILSETFQLLK | DADILSETFQLLI | 13 | 5 | 37201697 | A | T | HLA-A11:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre, patient_Tc_line | peptide_pulsed_APC | none | 12.983 | 5.5 | 2.664 | 0.158422 | null | null | -1.87901 | no | 0 | null | null | PMID:31887370 | Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma |
NDDR-1YAP0FVN2C-U | 4V2JUJEQ | Liver | Hepatocellular Carcinoma | C5orf42 | SNV | p.I1134K | 11 | DILSETFQLLK | DILSETFQLLI | 11 | 5 | 37201697 | A | T | HLA-A11:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre, patient_Tc_line | peptide_pulsed_APC | none | 3.101 | 1.8 | 0.978 | 0.09474 | 0.296 | null | -2.96262 | no | 0 | null | null | PMID:31887370 | Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma |
NDDR-0T85G4PK4N-4 | 4V2JUJEQ | Liver | Hepatocellular Carcinoma | C5orf42 | SNV | p.I1134K | 10 | ILSETFQLLK | ILSETFQLLI | 10 | 5 | 37201697 | A | T | HLA-A11:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre, patient_Tc_line | peptide_pulsed_APC | none | 0.675 | 0.5 | 0.762 | 0.072464 | 0.432 | null | -3.858778 | no | 0 | null | null | PMID:31887370 | Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma |
NDDR-JPW6QH0ZNW-D | 4V2JUJEQ | Liver | Hepatocellular Carcinoma | C5orf42 | SNV | p.I1134K | 9 | LSETFQLLK | LSETFQLLI | 9 | 5 | 37201697 | A | T | HLA-A11:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre, patient_Tc_line | peptide_pulsed_APC | none | 0.544 | 1.2 | 0.28 | 0.121928 | 0.316 | null | -3.752958 | no | 0 | null | null | PMID:31887370 | Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma |
NDDR-NPWGNEDF13-E | G4ZPYEDM | Skin | Skin Cutaneous Melanoma | DDX3X | SNV | p.E388K | 4 | FPKKIQMLA | FPKEIQMLA | 9 | X | 41345316 | G | A | HLA-B56:01 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 0.006 | 0.07 | 0.347 | 0.831153 | -1.374 | 0.920179 | 0.405465 | no | 0 | 4.161428 | Tumor Driver | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-1RZ65VX580-B | G4ZPYEDM | Skin | Skin Cutaneous Melanoma | ITGA9 | SNV | p.L548P | 7 | VTEKLQPTY | VTEKLQLTY | 9 | 3 | 37542539 | T | C | HLA-A01:01 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 0.02 | 0.12 | 0.02 | 0.281449 | 2.714 | 0.946856 | 1.609438 | no | 0 | 1.3091 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-5NDTKW9WVC-U | G6DBM54G | Skin | Skin Cutaneous Melanoma | VPS16 | SNV | p.S404F | 5 | LRAAFFGKCF | LRAASFGKCF | 10 | 20 | 2862814 | C | T | HLA-B27:05 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 2.327 | 0.8 | 0.612 | 0.411294 | 2.934 | 0.412664 | -0.018732 | no | 0 | 3.703167 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-MHSQEBMGSW-D | G6DBM54G | Skin | Skin Cutaneous Melanoma | CIT | SNV | p.P2056L | 4 | VRTLLSQVNK | VRTPLSQVNK | 10 | 12 | 119690296 | G | A | HLA-B27:05 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 0.829 | 0.4 | 1.059 | 0.659847 | 0.756 | 0.817271 | 0.578183 | no | 0 | 0.65081 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-M431P5K4KM-3 | G6DBM54G | Skin | Skin Cutaneous Melanoma | CASP1 | SNV | p.P172S | 8 | WRNILLLSLH | WRNILLLPLH | 10 | 11 | 105041480 | G | A | HLA-B27:05 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 2.113 | 1.2 | 0.462 | 0.79588 | -0.566 | null | -0.025235 | no | 0 | 2.91849 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-YZD3GSV3PV-C | F3XRZQLP | Skin | Skin Cutaneous Melanoma | FAM200A | SNV | p.S116F | 9 | IPLSDNTIF | IPLSDNTIS | 9 | 7 | 99548061 | G | A | HLA-B35:01 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 0.049 | 0.12 | 0.039 | 0.542263 | 1.964 | 0.042772 | -4.541121 | yes | 0 | 1.976985 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-QFKBAJAWPA-S | F3XRZQLP | Skin | Skin Cutaneous Melanoma | GRIN2B | SNV | p.E1104K | 5 | REFDKIELAY | REFDEIELAY | 10 | 12 | 13563928 | C | T | HLA-B41:02 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 0.527 | 2.5 | 0.137 | 0.473416 | 3.384 | 0.977014 | -0.564753 | no | 0 | -7.861448 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-3FYD6RDVNQ-7 | F3XRZQLP | Skin | Skin Cutaneous Melanoma | TBX4 | SNV | p.S271F | 5 | YPVIFKSIM | YPVISKSIM | 9 | 17 | 61480110 | C | T | HLA-B35:01 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 0.083 | 0.08 | 0.076 | 0.853465 | -0.268 | 0.949069 | 0.170345 | yes | 0 | -5.357024 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-J3PXJHBAC2-D | URSBQAUG | Skin | Skin Cutaneous Melanoma | FAM50B | SNV | p.E78K | 7 | DMKARQKALV | DMKARQEALV | 10 | 6 | 3850043 | G | A | HLA-B08:01 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 0.843 | 3 | 3.24 | 0.65091 | 0.1 | 0.521495 | 0.064934 | yes | 0 | 2.637761 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-BGT2WPZEN8-J | F3XRZQLP | Skin | Skin Cutaneous Melanoma | COL22A1 | SNV | p.D291N | 7 | FPQGLPNEY | FPQGLPDEY | 9 | 8 | 138826756 | C | T | HLA-B35:01 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | none | 0.003 | 0.09 | 0.016 | 0.566362 | 2.026 | 0.818258 | 0 | yes | 0 | 0.919263 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-51YCQP8A9M-3 | F3XRZQLP | Skin | Skin Cutaneous Melanoma | COL22A1 | SNV | p.D291N | 3 | LPNEYAFVTT | LPDEYAFVTT | 10 | 8 | 138826756 | C | T | HLA-B35:01 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 4.521 | 1 | 0.237 | 0.364148 | -1.422 | 0.05056 | 0.028721 | yes | 0 | 0.919263 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-B7GMHB69XA-S | F3XRZQLP | Skin | Skin Cutaneous Melanoma | COL22A1 | SNV | p.D291N | 3 | LPNEYAFVT | LPDEYAFVT | 9 | 8 | 138826756 | C | T | HLA-B35:01 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | TMC | 0.923 | 0.5 | 0.19 | 0.718165 | -1.422 | 0.499 | -0.327767 | yes | 0 | 0.919263 | null | PMID:28678778 | An immunogenic personal neoantigen vaccine for patients with Melanoma |
NDDR-2YDKRK2AD9-K | NGE5BUYC | Skin | Skin Cutaneous Melanoma | TTBK2 | SNV | p.S1088L | 9 | RPHHDQRSL | RPHHDQRSS | 9 | 15 | 42745988 | G | A | HLA-B07:02 | CD8 | ELISPOT, ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.008 | 0.05 | 0.1 | 0.729896 | 0.654 | 0.118015 | -4.77702 | no | 0 | 0.111698 | null | PMID:28678784 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer |
NDDR-VAPV22ZYG6-H | LC3W5VRX | Skin | Skin Cutaneous Melanoma | KIF26B | SNV | p.N256S | 2 | SSYTGFANK | SNYTGFANK | 9 | 1 | 245367135 | A | G | HLA-A11:01 | CD8 | ELISPOT, ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.007 | 0.3 | 0.006 | 0.334228 | 0.99 | 0.970843 | -4.330733 | no | 0 | 1.124709 | null | PMID:28678784 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer |
NDDR-KWE7NJQDW7-I | LYXKV47S | Skin | Skin Cutaneous Melanoma | SPOP | SNV | p.N147I | 7 | FLLDEAIGL | FLLDEANGL | 9 | 17 | 49619021 | T | A | HLA-A02:01 | CD8 | ELISPOT, ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.009 | 0.8 | 0.042 | 0.644657 | 0.738 | 0.943178 | -0.893818 | no | 1 | 2.900451 | Other Tumor Driver | PMID:28678784 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer |
NDDR-KYVW6EZ6RX-E | OKQRI23E | Skin | Skin Cutaneous Melanoma | NARFL | SNV | p.E62K | 1 | KSQREEVRR | ESQREEVRR | 9 | null | null | null | null | HLA-A31:01 | CD8 | ELISPOT, ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.411 | 1.3 | 0.683 | 0.025452 | 1.666 | null | -2.183067 | no | 0 | null | null | PMID:28678784 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer |
NDDR-NFN8N8118Y-F | VU5HBL4S | Skin | Skin Cutaneous Melanoma | PPFIA4 | SNV | p.S709N | 4 | MRMNQGVCC | MRMSQGVCC | 9 | 1 | 203053848 | G | A | HLA-B39:06 | CD8 | ELISPOT, ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.418 | 0.09 | 3.039 | 0.972498 | 0.486 | 0.033837 | 0.42601 | no | 0 | -0.786497 | null | PMID:28678784 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer |
NDDR-73G4NR2F2Q-7 | LYXKV47S | Skin | Skin Cutaneous Melanoma | CDK4 | SNV | p.R24L | 2 | ALDPHSGHFV | ARDPHSGHFV | 10 | 12 | 57751647 | C | A | HLA-A02:01 | CD8 | ELISPOT, ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.085 | 1.2 | 0.065 | 0.469788 | 0.228 | 0.668099 | -4.919637 | no | 1 | 4.89147 | Tumor Driver | PMID:28678784 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer |
NDDR-B1DKTHN336-H | 5DJDBZPW | Skin | Skin Cutaneous Melanoma | SYTL4 | SNV | p.S363F | 6 | GRIAFFLKY | GRIAFSLKY | 9 | X | 100687163 | G | A | HLA-B27:05 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | MS | 0.009 | 0.4 | 0.001 | 0.914394 | 3.272 | 0.977758 | 0.117783 | no | 1 | -2.573045 | null | PMID:27869121 | Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry |
NDDR-VZ6AX01GXJ-0 | 5DJDBZPW | Skin | Skin Cutaneous Melanoma | NCAPG2 | SNV | p.P333L | 2 | KLILWRGLK | KPILWRGLK | 9 | 7 | 158680743 | G | A | HLA-A03:01 | CD8 | ELISPOT | patient_TIL | peptide_pulsed_APC | MS | 0.184 | 0.4 | 0.122 | 0.435756 | 0.762 | 0.861472 | -3.519785 | no | 1 | 2.653482 | null | PMID:27869121 | Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry |
NDDR-PBXJS7YJDT-A | 5DJDBZPW | Skin | Skin Cutaneous Melanoma | AKAP6 | SNV | p.M1482I | 6 | KLKLPIIMK | KLKLPMIMK | 9 | 14 | 32822259 | G | C | HLA-A03:01 | CD8 | ELISPOT | patient_TIL | peptide_pulsed_APC | MS | 0.006 | 0.12 | 0.001 | 0.468706 | 0.62 | 0.968833 | -0.154151 | no | 1 | -0.385819 | null | PMID:27869121 | Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry |
NDDR-WKQY9KFRV9-K | PKPFBJDF | Skin | Skin Cutaneous Melanoma | NOP16 | SNV | p.P169L | 9 | SPGPVKLEL | SPGPVKLEP | 9 | 5 | 176384171 | G | A | HLA-B07:02 | CD8 | ELISPOT | patient_TIL | peptide_pulsed_APC | MS | 0.011 | 0.7 | 0.028 | 0.235061 | 0.112 | null | -4.500819 | no | 1 | 2.721895 | null | PMID:27869121 | Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry |
NDDR-C98AVT8VA9-K | I4HS6WN2 | Skin | Skin Cutaneous Melanoma | CSNK1A1 | SNV | p.S27L | 2 | GLFGDIYLA | GSFGDIYLA | 9 | 5 | 149550885_149550886 | TC | CT | HLA-A02:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.052 | 1.5 | 0.046 | 0.590849 | -0.414 | 0.312295 | -4.006284 | no | 1 | 3.029707 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-FF8XNFEPVF-X | 74LV6E74 | Skin | Skin Cutaneous Melanoma | MATN2 | SNV | p.E226K | 1 | KTLTSVFQK | ETLTSVFQK | 9 | 8 | 97931486 | G | A | HLA-A11:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.004 | 0.01 | 0.001 | 0.441139 | 0.686 | 0.926989 | -3.102342 | no | 1 | 2.156137 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-894FCPT0FK-1 | 74LV6E74 | Skin | Skin Cutaneous Melanoma | CDK12 | SNV | p.E928K | 5 | CILGKLFTK | CILGELFTK | 9 | 7 | 40063036 | G | A | HLA-A11:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.279 | 1.1 | 0.021 | 0.14316 | 0.56 | 0.34099 | -0.327213 | no | 1 | 2.569549 | Tumor Driver | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-AYRXPFMZNE-W | 74LV6E74 | Skin | Skin Cutaneous Melanoma | CDK12 | SNV | p.E928K | 5 | CILGKLFTKK | CILGELFTKK | 10 | 7 | 40063036 | G | A | HLA-A11:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 1.908 | 1.2 | 0.466 | 0.20399 | 0.56 | 0.794302 | 0.048869 | no | 0 | 2.569549 | Tumor Driver | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-YRY5RYAEAT-A | I4HS6WN2 | Skin | Skin Cutaneous Melanoma | CSNK1A1 | SNV | p.S27L | 2 | GLFGDIYLAI | GSFGDIYLAI | 10 | 5 | 149550885_149550886 | TC | CT | HLA-A02:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.369 | 0.8 | 0.185 | 0.573459 | 0.656 | 0.921601 | -3.064454 | no | 1 | 3.029707 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-EMJNAQ3KAZ-G | I4HS6WN2 | Skin | Skin Cutaneous Melanoma | HAUS3 | SNV | p.T160A | 7 | ILNAMIAKI | ILNAMITKI | 9 | 4 | 2240469 | T | C | HLA-A02:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.43 | 0.5 | 0.15 | 0.647834 | 0.322 | 0.879551 | 0.750579 | no | 1 | 0.52195 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-BGR5R73328-J | 74LV6E74 | Skin | Skin Cutaneous Melanoma | MATN2 | SNV | p.E226K | 1 | KTLTSVFQKK | ETLTSVFQKK | 10 | 8 | 97931486 | G | A | HLA-A11:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.054 | 0.01 | 0.069 | 0.448778 | 0.686 | 0.963817 | -2.580497 | no | 0 | 2.156137 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-545JRB33M5-G | J5PM7M2Y | Skin | Skin Cutaneous Melanoma | PLEKHM2 | SNV | p.H1005Y | 10 | LTDDRLFTCY | LTDDRLFTCH | 10 | 1 | 15732428 | C | T | HLA-A01:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.009 | 0.01 | 0.006 | 0.695479 | 2.652 | 0.412145 | -4.333653 | no | 0 | 5.051104 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-F477MEXVTB-T | I4HS6WN2 | Skin | Skin Cutaneous Melanoma | GAS7 | SNV | p.H225Y | 9 | SLADEAEVYL | SLADEAEVHL | 10 | 17 | 9934186 | G | A | HLA-A02:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.095 | 2.5 | 0.045 | 0.343229 | 1.054 | 0.969244 | -0.408968 | no | 1 | 5.458259 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-1NGBH26P25-G | J5PM7M2Y | Skin | Skin Cutaneous Melanoma | PPP1R3B | SNV | p.P176H | 5 | YTDFHCQYV | YTDFPCQYV | 9 | 8 | 9141125 | G | T | HLA-A01:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC | none | 0.224 | 1.3 | 0.005 | 0.684944 | -0.158 | 0.901694 | -0.117783 | no | 1 | 2.600531 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-3397S1P89B-T | J5PM7M2Y | Skin | Skin Cutaneous Melanoma | PPP1R3B | SNV | p.P176H | 5 | YTDFHCQYVK | YTDFPCQYVK | 10 | 8 | 9141125 | G | T | HLA-A01:01 | CD8 | ELISPOT, ICS | patient_TIL | peptide_pulsed_APC, tumor_cells | endogenous(HLA-block) | 0.841 | 1.2 | 0.145 | 0.480959 | -0.008 | 0.912707 | 0.144291 | no | 1 | 2.600531 | null | PMID:23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
NDDR-4H8V6XSZ4F-X | 6K4YGFNF | Skin | Skin Cutaneous Melanoma | KIF16B | SNV | p.L1009P | 2 | APARLERRHSA | ALARLERRHSA | 11 | 20 | 16378976 | A | G | HLA-B07:02 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.459 | 0.7 | 2.211 | 0.022523 | -0.818 | 0.78183 | -3.671241 | no | 0 | 1.905253 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-1C3G4QSC15-G | 6K4YGFNF | Skin | Skin Cutaneous Melanoma | FLNA | SNV | p.R2049C | 1 | CVRVSGQGL | RVRVSGQGL | 9 | X | 154353082 | G | A | HLA-B07:02 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 1.384 | 1.8 | 0.386 | 0.063144 | 1.114 | 0.953143 | 2.305479 | no | 0 | 7.162795 | Other Tumor Driver | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-WYJW76M06R-8 | TOGZJCOT | Skin | Skin Cutaneous Melanoma | PDS5A | SNV | p.Y1000F;H1007Y | 1,8 | FVVPYMIYLL | YVVPYMIHLL | 10 | null | null | null | null | HLA-C03:03 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 4.104 | 4.5 | 0.127 | 0.088732 | 0.976 | 0.971609 | 1.044545 | yes | 0 | 3.19243 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-XJ3RMEC41A-S | TOGZJCOT | Skin | Skin Cutaneous Melanoma | MAGEA6 | SNV | p.E168K | 1 | KVDPIGHVY | EVDPIGHVY | 9 | X | 152767149 | C | T | HLA-A01:01 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.011 | 0.02 | 0.006 | 0.538203 | 2.85 | 0.975792 | 0.606136 | no | 0 | 2.919136 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-BS3218G751-C | TOGZJCOT | Skin | Skin Cutaneous Melanoma | MAGEA6 | SNV | p.E168K | 1 | KVDPIGHVYIF | EVDPIGHVYIF | 11 | null | null | null | null | HLA-C05:01 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.207 | 20 | 0.147 | 0.218765 | 2.46 | 0.972332 | -1.486205 | no | 0 | 2.919136 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-YXV2AQ4573-E | TOGZJCOT | Skin | Skin Cutaneous Melanoma | MAGEA6 | SNV | p.E168K | 3 | LMKVDPIGHVY | LMEVDPIGHVY | 11 | null | null | null | null | HLA-B15:01 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.178 | 0.04 | 0.557 | 0.094909 | 3.084 | 0.975792 | -1.548041 | no | 0 | 2.919136 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-0CQM64X89C-U | TOGZJCOT | Skin | Skin Cutaneous Melanoma | MED13 | SNV | p.P1691S | 6 | SVQIISCQY | SVQIIPCQY | 9 | null | null | null | null | HLA-A30:02 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.122 | 2.5 | 0.031 | 0.996467 | 3.044 | 0.965587 | 0.541341 | no | 0 | 2.53319 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-8V8HWA94GP-6 | TOGZJCOT | Skin | Skin Cutaneous Melanoma | MED13 | SNV | p.P1691S | 5 | VQIISCQY | VQIIPCQY | 8 | 17 | 61961773 | G | A | HLA-A30:02 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 1.365 | 4 | 11.228 | 0.965486 | 3.326 | 0.965587 | 0.328301 | no | 0 | 2.53319 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-R8DTB8R876-H | TOGZJCOT | Skin | Skin Cutaneous Melanoma | MED13 | SNV | p.P1691S | 5 | VQIISCQY | VQIIPCQY | 8 | 17 | 61961773 | G | A | HLA-B15:01 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.34 | 0.12 | 0.377 | 0.395824 | 3.326 | 0.965587 | 0.102098 | no | 0 | 2.53319 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-NG120S2XBY-F | TOGZJCOT | Skin | Skin Cutaneous Melanoma | MED13 | SNV | p.P1691S | 7 | VSVQIISCQY | VSVQIIPCQY | 10 | null | null | null | null | HLA-A30:02 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.491 | 3.5 | 1.446 | 0.992012 | 3.218 | 0.965587 | -0.085823 | no | 0 | 2.53319 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-HHJP6E4WJE-W | TOGZJCOT | Skin | Skin Cutaneous Melanoma | MED13 | SNV | p.P1691S | 7 | VSVQIISCQY | VSVQIIPCQY | 10 | null | null | null | null | HLA-A01:01 | CD8 | multimer, ELISPOT | PBMC_pre, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.715 | 0.12 | 1.623 | 0.058955 | 3.218 | 0.965587 | 0.035591 | no | 0 | 2.53319 | null | PMID:26901407 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients |
NDDR-NATBNFYEAK-1 | YQSS3IYL | Ovary | Ovarian Cancer | HS6ST1 | SNV | p.S405I | 4 | DYMIHIIEKW | DYMSHIIEKW | 10 | 2 | 128268184 | C | A | HLA-A23:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre | peptide_pulsed_APC | none | 0.328 | 0.9 | 0.215 | 0.596565 | 0.846 | 0.959502 | 0.291755 | no | 0 | 4.582285 | null | PMID:29545564 | Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer |
NDDR-BHHDNDR6ZQ-7 | VMHDDH4X | Ovary | Ovarian Cancer | COPG2 | SNV | p.T37I | 1 | IPINPRRCL | TPINPRRCL | 9 | 7 | 130666910 | G | A | HLA-B07:02 | CD8 | ELISPOT, ICS, multimer | PBMC_pre | peptide_pulsed_APC | none | 0.025 | 0.06 | 0.434 | 0.808351 | 0.486 | 0.764573 | 0.083382 | no | 0 | 3.153886 | null | PMID:29545564 | Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer |
NDDR-RABCTRZ18B-T | TKJU56TT | Ovary | Ovarian Cancer | SEPT9 | SNV | p.R289H | 7 | SILEQMHRK | SILEQMRRK | 9 | null | null | null | null | HLA-A11:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre | peptide_pulsed_APC | none | 0.02 | 0.6 | 0.128 | 0.189973 | 0.682 | null | -1.848455 | no | 1 | null | null | PMID:29545564 | Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer |
NDDR-81PF6HAJE6-H | Q2ITNIFI | Ovary | Ovarian Cancer | PDPN | SNV | p.G222C | 3 | FICAIIVVV | FIGAIIVVV | 9 | 1 | 13614365 | G | T | HLA-A02:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre | peptide_pulsed_APC | none | 1.217 | 0.4 | 0.024 | 0.68459 | 0.196 | 0.680153 | 0.893544 | no | 0 | 2.404058 | null | PMID:29545564 | Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer |
NDDR-WAWJVEYCNM-3 | Q2ITNIFI | Ovary | Ovarian Cancer | KIR2DS4 | SNV | p.I7S | 1 | SMACVGFFL | IMACVGFFL | 9 | null | null | null | null | HLA-A02:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre | peptide_pulsed_APC | none | 1.021 | 1.9 | 0.068 | 0.363276 | 1.164 | 0.623868 | -0.075436 | no | 0 | -5.058894 | null | PMID:29545564 | Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer |
NDDR-B9FTPHZX9N-4 | GNQ75CJK | Ovary | Ovarian Cancer | USP47 | SNV | p.V170L | 5 | TSDYLSQSY | TSDYVSQSY | 9 | 11 | 11892058 | G | C | HLA-A01:01 | CD8 | ELISPOT, ICS, multimer | PBMC_pre | peptide_pulsed_APC | none | 0.002 | 0.4 | 0.004 | 0.252534 | 2.636 | 0.971324 | 0 | no | 0 | 0.7376 | null | PMID:29545564 | Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer |
NDDR-8KVBFCA09D-V | 4DKUZH62 | Ovary | Ovarian Cancer | ODZ3 | SNV | p.A2490V | 9 | GAQSWLWFV | GAQSWLWFA | 9 | 4 | 182799720 | C | T | HLA-A02:11 | CD8 | ELISPOT, ICS, multimer | PBMC_pre | peptide_pulsed_APC | none | 0.923 | 0.7 | 0.142 | 0.975253 | 0.216 | null | -1.199847 | yes | 0 | null | null | PMID:29545564 | Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer |
NDDR-453FFPEY00-B | YG2NSK3U | Brain | Glioblastoma (GBM) | IDH1 | SNV | p.R132H | 10 | GWVKPIIIGH | GWVKPIIIGR | 10 | 2 | 208248388 | C | T | HLA-B58:01 | CD8 | ICS | PBMC_postVax | peptide_pulsed_APC | none | 29.107 | 49 | 20.4 | 0.019775 | -0.336 | 0.868231 | -0.230244 | yes | 0 | 5.024923 | Tumor Driver | PMID:30733620 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
NDDR-W3ZRQB9QB9-K | TBH3PNXF | Brain | Glioblastoma (GBM) | SLC44A2 | SNV | p.L204M | 4 | ITDMVEGAKK | ITDLVEGAKK | 10 | null | null | null | null | HLA-A03:01 | CD8 | ICS | PBMC_postVax | peptide_pulsed_APC | none | 2.002 | 2.5 | 1.811 | 0.177257 | 0.114 | 0.373603 | -0.165362 | no | 0 | 5.43825 | null | PMID:30733620 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
NDDR-Q35B4A9CVQ-7 | MYK5YWYV | Brain | Glioblastoma (GBM) | RFX1 | SNV | p.T324M | 2 | YMQTASTSYY | YTQTASTSYY | 10 | null | null | null | null | HLA-A01:01 | CD8 | ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.332 | 1 | 0.059 | 0.130624 | 2.824 | 0.966927 | 2.221616 | no | 0 | 1.410422 | null | PMID:30733620 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
NDDR-0EZ996H7KA-S | MYK5YWYV | Brain | Glioblastoma (GBM) | EPHB3 | SNV | p.R677W | 7 | YTERQRWDF | YTERQRRDF | 9 | null | null | null | null | HLA-A01:01 | CD8 | ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.615 | 5 | 0.469 | 0.021732 | 2.126 | 0.088796 | -0.998957 | no | 0 | 2.61188 | null | PMID:30733620 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
NDDR-A9KQRJ0YTC-U | ZLZLTBFT | Brain | Glioblastoma (GBM) | NUCB1 | SNV | p.V300M | 8 | RLRMREHMMK | RLRMREHVMK | 10 | null | null | null | null | HLA-A03:01 | CD8 | ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.167 | 0.15 | 0.361 | 0.359162 | 0.784 | 0.947325 | -0.247982 | no | 0 | 5.924214 | null | PMID:30733620 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
NDDR-44QS1THAG3-E | F3UNKL3Y | Brain | Glioblastoma (GBM) | RBKS | SNV | p.T95A | 7 | KQNDISAEF | KQNDISTEF | 9 | null | null | null | null | HLA-B15:01 | CD8 | ICS | PBMC_postVax | peptide_pulsed_APC | none | 0.004 | 0.02 | 0.002 | 0.295377 | 2.718 | 0.966161 | 0.287682 | no | 0 | 0.333136 | null | PMID:30733620 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
NDDR-6J2G3WKA08-J | GVYOONV4 | Brain | Glioblastoma (GBM) | SLC9A6 | SNV | p.N572I | 10 | SAWLFRMWYI | SAWLFRMWYN | 10 | null | null | null | null | HLA-A02:01 | CD8 | ICS | PBMC_postVax | peptide_pulsed_APC | none | 13.515 | 6 | 1.186 | 0.176609 | 1.012 | 0.022848 | -1.778226 | no | 0 | 2.120799 | null | PMID:30733620 | Actively personalized vaccination trial for newly diagnosed glioblastoma |
NDDR-EDQDWAWTP4-F | PFMINZ56 | Breast | Breast Cancer | ECPAS | SNV | p.S186F | 10 | MPYGYVLNEF | MPYGYVLNES | 10 | 9 | 111437072_111437073 | CA | TT | HLA-B35:01 | CD8 | ELISPOT, 4-1BB | patient_TIL, TCR_clone | peptide_pulsed_APC, TMC_minigene | TMC | 0.056 | 0.05 | 0.018 | 0.478653 | 2.356 | 0.422068 | -4.303582 | yes | 0 | 4.401606 | null | PMID:29867227 | Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer |
NDDR-Y3TJTRGEMA-S | PFMINZ56 | Breast | Breast Cancer | CADPS2 | SNV | p.R1266H | 8 | TYDTVHRHL | TYDTVHRRL | 9 | 7 | 122320259 | C | T | HLA-C04:01 | CD8 | ELISPOT, 4-1BB | patient_TIL, TCR_clone | peptide_pulsed_APC, TMC_minigene | TMC | 0.006 | 25 | 0.001 | 0.660042 | 0.732 | 0.958242 | -0.287682 | no | 0 | 3.089786 | null | PMID:29867227 | Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer |
NDDR-9MF2CZ9EEC-U | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | PORCN | SNV | p.H346Y | 8 | LLHGFSFYL | LLHGFSFHL | 9 | X | 48515902 | C | T | HLA-A02:01 | CD8 | multimer, 51Cr | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.086 | 0.15 | 0.015 | 0.734435 | 1.068 | 0.977941 | 0.059898 | no | 1 | 1.886384 | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-7HFGTRT2KG-Y | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | AKAP9 | SNV | p.L947F | 5 | RLSDFSEQL | RLSDLSEQL | 9 | 7 | 92002801 | C | T | HLA-A02:01 | CD8 | multimer, 51Cr | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.024 | 0.4 | 0.069 | 0.499613 | 1.168 | 0.977036 | -0.223144 | no | 1 | 2.055005 | Other Tumor Driver | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-R6WWVF6EQ6-H | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | RASAL2 | SNV | p.P637S | 4 | IMSSSLFNL | IMSPSLFNL | 9 | 1 | 178452552 | C | T | HLA-A02:01 | CD8 | multimer | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC | none | 0.236 | 0.6 | 0.066 | 0.306679 | 1.032 | 0.969002 | 1.352958 | no | 1 | 1.331619 | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-108MYSE1VC-U | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | CDKN2A | SNV | p.P114L | 2 | LLVDLAEEL | LPVDLAEEL | 9 | 9 | 21971018 | G | A | HLA-A02:01 | CD8 | multimer | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC | none | 0.1 | 2.5 | 0.174 | 0.478684 | 1.164 | 0.957983 | -4.712319 | no | 0 | 1.258459 | Tumor Driver | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-1G2Z2Z3NBX-E | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | PDE7B | SNV | p.G113R | 1 | RMWDFDIFL | GMWDFDIFL | 9 | 6 | 136149105 | G | A | HLA-A02:01 | CD8 | multimer | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC | none | 0.022 | 0.09 | 0.005 | 0.719792 | 1.63 | 0.968043 | -0.127833 | no | 0 | -1.260168 | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-SEA7CN1KAX-E | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | GCN1L1 | SNV | p.P274L | 6 | SLLRSLENV | SLLRSPENV | 9 | 12 | 120177464 | G | A | HLA-A02:01 | CD8 | multimer, 51Cr | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.06 | 0.4 | 0.081 | 0.546661 | 0.416 | null | -0.559616 | no | 1 | null | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-EZBD3HKP1K-1 | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | SOCS6 | SNV | p.P134L | 9 | SLRSHHYSL | SLRSHHYSP | 9 | 18 | 70325069 | C | T | HLA-B08:01 | CD8 | multimer, 51Cr | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.006 | 0.6 | 0.023 | 0.480798 | 1.118 | 0.409931 | -5.372961 | yes | 1 | 3.067294 | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-5GDBWJVZ1H-Z | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | POGK | SNV | p.P46L | 3 | WVLALFDEV | WVPALFDEV | 9 | 1 | 166846616 | C | T | HLA-A02:01 | CD8 | multimer | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC, TMC_minigene | none | 3.02 | 4.5 | 0.733 | 0.347158 | 0.314 | 0.288239 | -0.050995 | no | 0 | 3.56306 | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-T0AFTDJ9PD-V | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | ZDBF2 | SNV | p.S2228L | 3 | YILKYSVFL | YISKYSVFL | 9 | 2 | 206311211 | C | T | HLA-A02:01 | CD8 | multimer, 51Cr | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC, TMC_minigene | TMC | 0.193 | 0.5 | 0.027 | 0.61301 | 0.96 | 0.963955 | -0.179728 | no | 1 | -0.664534 | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-47041KC807-I | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | GAS7 | SNV | p.S270F | 1 | FLGEAWAQV | SLGEAWAQV | 9 | 17 | 9934242 | G | A | HLA-A02:01 | CD8 | multimer | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC | none | 0.055 | 0.9 | 0.392 | 0.592199 | -0.264 | 0.969671 | -0.828949 | no | 0 | 5.458259 | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-JV00FYYZJR-8 | 6TP4IBLE | Skin | Skin Cutaneous Melanoma | PNPLA4 | SNV | p.P100S | 3 | ILSPSAHEL | ILPPSAHEL | 9 | X | 7921826 | G | A | HLA-A02:01 | CD8 | multimer | PBMC_pre, PBMC_postVax, patient_TIL | peptide_pulsed_APC | none | 0.024 | 1.4 | 0.196 | 0.431042 | 0.922 | 0.976745 | -0.432864 | no | 0 | 2.462092 | null | PMID:31685621 | Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens |
NDDR-N6NTA1JDTE-W | 352WTYXA | Ovary | Ovarian Cancer | PPM1F | SNV | p.C259Y | 7 | FLAPLFLVLL | FLAPLFCVLL | 10 | 5 | 88203038 | T | G | HLA-A24:02 | CD8 | ELISPOT | PBMC_postVax, patient_TIL | peptide_pulsed_APC | none | 8.36 | 3 | 1.457 | 0.027011 | 0.736 | null | -0.252377 | no | 0 | 0.780394 | null | PMID:32660279 | Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites |
NDDR-MCK2ZAJ8GQ-7 | R7NU4BAT | Brain | Glioblastoma (GBM) | WDR63 | SNV | p.T690M | 8 | FYNDIILMV | FYNDIILTV | 9 | 1 | 85124208 | C | T | HLA-C06:02 | CD8 | ELISPOT | PBMC_postVax | peptide_pulsed_APC | none | 0.042 | 34 | 0.001 | 0.937943 | 0.026 | null | 0.518794 | no | 0 | null | null | PMID:30906654 | Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma |
NDDR-S6DN480CYD-V | XD6MQQ3M | Ovary | Ovarian Cancer | SSC4D | SNV | p.D85Y | 9 | YGTGHILLY | YGTGHILLD | 9 | 7 | 76397626 | C | A | HLA-B35:01 | CD8 | 4-1BB, ICS | PBMC_pre | peptide_pulsed_APC, tumor_cells | none | 0.347 | 5 | 0.095 | 0.34794 | 2.496 | 0.067292 | -5.180179 | yes | 0 | 1.241352 | null | PMID:31069153 | Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer |
NDDR-VS85BXHK0E-W | XD6MQQ3M | Ovary | Ovarian Cancer | SSC4D | SNV | p.D85Y | 9 | YGTGHILLY | YGTGHILLD | 9 | 7 | 76397626 | C | A | HLA-C12:03 | CD8 | 4-1BB, ICS | PBMC_pre | peptide_pulsed_APC, tumor_cells | none | 0.117 | 18 | 0.008 | 0.062591 | 2.496 | 0.067292 | -5.774366 | yes | 0 | 1.241352 | null | PMID:31069153 | Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer |
NDDR-HR56JF3PKD-V | XD6MQQ3M | Ovary | Ovarian Cancer | NAV1 | SNV | p.K349M | 1 | MAKAKAVAL | KAKAKAVAL | 9 | null | null | null | null | HLA-B35:01 | CD8 | 4-1BB, ICS | PBMC_pre | peptide_pulsed_APC, tumor_cells | none | 0.841 | 1.2 | 1.189 | 0.061466 | 1.048 | 0.941944 | -1.781601 | yes | 0 | 0.481402 | null | PMID:31069153 | Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer |
NDDR-C5YZS7EBSD-V | XD6MQQ3M | Ovary | Ovarian Cancer | TRO | SNV | p.S598C | 5 | SVGACGFSY | SVGASGFSY | 9 | X | 54930991 | C | G | HLA-B35:01 | CD8 | 4-1BB, ICS | PBMC_pre | peptide_pulsed_APC, tumor_cells | none | 1.793 | 2.5 | 0.289 | 0.02987 | 2.782 | null | 1.156591 | yes | 0 | 1.602932 | null | PMID:31069153 | Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer |
End of preview.